October 6-7, 2022

Milan, Italy - Cloisters of San Barnaba

Chairs:
Pietro Lampertico and Heiner Wedemeyer

In case of non-receipt of the activation email click here

Poster Exhibition

Diagnosis and Biomarkers

P 1
Virological diagnosis of Hepatitis Delta Virus infection in France: results of ten years of experience in organizing national quality controls

A. Gerber¹, S. Brichler^1,2, S. Dziri¹, C. Alloui¹, E. Gordien^1,2, F. Le Gal^1,2

¹Centre National de Référence pour les virus des hépatites B, C et Delta, Laboratoire de microbiologie clinique, Hôpital Avicenne Assistance Publique - Hôpitaux de Paris, Bobigny, France, ²INSERM U955, Équipe 18, Créteil, France

Download

P 2
Divergent patterns of HBV-RNA AND HBcrAg levels in untreated chronic hepatitis Delta: a large European cross-sectional study

E. Degasperi¹, A. Loglio¹, C. Scholtes^2,3,4, S. Colonia Uceda Renteria⁵, C. Charre^2,3,4, F. Facchetti¹, M.L. Plissonnier², D. Sambarino¹, F. Ceriotti⁵, A. De Silvestri⁶, B. Testoni², M. Levrero^2,4,7, F. Zoulim^2,4,7, P. Lampertico^1,8

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²INSERM U1052 - Cancer Research Center of Lyon (CRCL), Lyon, France, ³University Claude Bernard Lyon 1 (UCBL1), University of Lyon, Lyon, France, ⁴Department of Virology, Hospices Civils de Lyon, Lyon, France, ⁵Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Virology Unit, Milan, Italy, ⁶Servizio di Epidemiologia Clinica e Biometria, Direzione Scientifica - Fondazione IRCCS Policlinico san Matteo, Pavia, Italy, ⁷Department of Hepatology, Hospices Civils de Lyon, Lyon, ⁸CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Download

P 3
Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real world experience from Avicenne University Hospital, France

S. Brichler^1,3,4, D. Roulot^2,3,4, S. Dziri¹, A. Gerber¹, F. Le Gal^1,4, H. Delagrèverie^1,3, C. Alloui^1,4, E. Gordien^1,3,4

¹Virology Unit, Avicenne Hospital, Bobigny, France, ²Hepatology Unit, Avicenne Hospital, Bobigny, France, ³Sorbonne Paris Nord University, Bobigny, France, ⁴INSERM U955, Team 18, Créteil, France

Download

P 4
HBcrAg to quantitative anti-HBc IgG ratio predicts long-term outcomes in chronic hepatitis D patients

G.P. Caviglia¹, A. Olivero¹, G. Troshina¹, A. Nicolosi¹, A. Risso¹, M. Rizzetto¹, G.M. Saracco^1,2, A. Ciancio^1,2

¹Department of Medical Sciences, University of Turin, Turin, Italy, ²Gastroenterology Unit, Città della Salute e della Scienza - Molinette Hospital, Turin, Italy

Download

P 5
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection

R. Salpini¹, L. Piermatteo¹, S. D’Anna¹, U.S. Gill², A. Battisti^1,2, M. Alkhatib¹, R. Scutarisup>1, E. Andreassi¹, K.M.A. Ho², F. Ceccherini-Silberstein¹, C. Usai², P.T.F. Kennedy², V. Svicher¹

¹University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy, ²Barts Liver Centre, Immunobiology, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom

Download

P 6
Clinical long-term outcome of hepatitis delta compared to HBV monoinfection

¹A. Wranke¹, B. Calle Serrano¹, B. Heidrich¹, K. Deterding¹, J. Kirschner¹, B. Bremer¹, M. Cornberg¹, M. P. Manns¹, H. Wedemeyer¹

¹Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

Download

Epidemiology

P 7
Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study

E. Cordua⁵, M. Pisaturo^1,2, L. Alessio^1,3, A. Di Fraia¹, M. Macera^1,4, C. Minichini¹, L. Onorato^1,6, G. Scotto^7,8, G. Di Caprio^2,5, F. Calò^1,4, C. Sagnelli^1,6, N. Coppola

¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Italy, ²Medical Center, Centro Sociale ex Canapificio, Caserta, Italy, ³Medical Center, Centro di Accoglienza “La tenda di Abramo”, Caserta, Italy, ⁴Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, ⁵Infectious Diseases Unit, AORN Sant’Anna e San Sebastiano, Caserta, Italy, ⁶Medical center, Centro Suore Missionarie della Carità, Naples, Italy, ⁷Medical center, Centro Borgoroma, Foggia, Italy, ⁸Infectious Diseases Unit, Foggia, Italy

Download

P 8
Evaluating screening rates for hepatitis D in hepatitis B patients

J. Strzepka¹, M. Bhagwat¹, C. Aloman¹, N. Reau¹

¹Rush University Medical Center, Chicago, USA

Download

P 9
Molecular clock analysis reveals an ancient origin but a recent radiation of hepatitis Delta virus in humans

S. Tomba^1,2, C. Rodriguez^3,4,5, S. Brichler^1,2,3, S. Fourati^3,4,5A. Gerber^1,2, J.M. Pawlotsky^3,4,5, E. Gordien^1,2,3, S. Hué⁶, F. Le Gal^1,2,3

¹Laboratoire de microbiologie médicale, hôpital Avicenne (AP-HP), Bobigny, France, ²Laboratoire associé au Centre national de référence des virus des hépatites B, C et Delta, pour le virus de l’hépatite Delta, Bobigny, France, ³Unité INSERM U955, équipe n° 18, Université Paris Est, Créteil, France, ⁴Laboratoire de virologie, hôpital Henri Mondor (AP-HP), Créteil, France, ⁵Centre national de référence des virus des hépatites B, C et Delta, Créteil, France, ⁶Department of Infectious Disease Epidemiology Faculty of Epidemiology & Population Health London School of Hygiene & Tropical Medicine (LSHTM), London, UK

Download

P 10
Demographic features of HDV-infected patients from Republic of Moldova

A. Turcanu ¹, E. Cebanu ¹, L. Andries ¹, P. Pineau ²

¹State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Republic of Moldova, ²Unité “Organisation nucléaire et Oncogenèse”, INSERM U993, Institut Pasteur, 28, rue du Docteur Roux, 75015 Paris, France ²

Download

P 11
High molecular diversity and remarkable geographical distribution of hepatitis Delta virus strains that are spreading in Cameroon

A. Gerber¹, J. Delors Mfonkou², S. Brichler^1,3, F. Le Gal^1,3, R. Njouom², E. Gordien ^1,3

Download

P 12
Evaluating Hepatitis Delta virus disease prevalence, incidence and patient characteristics among adults in Italy in the outpatient setting

P. Lampertico^1,2, V. Perrone ³, D. Sangiorgi ³, M. Dovizio ³, L. Degli Esposti ³, C. Kim ⁴, A. Kaushik ⁴

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ³CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna, Italy, ⁴HEOR - Global Value & Access, Gilead Sciences, California, USA

Download

P 13
Real-world analysis of healthcare resource utilization and costs among diagnosed Hepatitis D patients within the outpatient setting in Italy

P. Lampertico^1,2, V. Perrone ³, D. Sangiorgi ³, M. Dovizio ³, L. Esposti ³, C. Kim ⁴, A. Kaushik ⁴

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ³CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna, Italy, ⁴HEOR - Global Value & Access, Gilead Sciences, California, USA

Download

P 14
Evaluation of HDV prevalence in outpatient clinic for infectious disease: from low to high endemic countries

A. Di Lorenzo¹, S. Tedde¹, P.G. Pace¹, A. Lodi¹, M. Zordan¹, F. Barreca¹, L. Ansaldo¹, D. Checchi¹, A. Crea¹, F. Caldara¹, T. Mulas¹, L. Ferrari¹, M. Compagno¹, G. De Simone¹, E. Teti¹, M. Iannetta¹, M. Andreoni¹, A.M. Geretti¹, L. Sarmati¹

¹Clinic of Infectious Diseases, Tor Vergata University Hospital, Rome, Italy

Download

P 15
The burden of HDV infection: a ten-years’ experience of a Sicilian tertiary centre of liver disease

G.E.M. Rizzo^1,2,3, D. Ferraro ⁴, G. Rancatore¹, P. Graceffa¹, G. Falco¹, C. La Mantia¹, V. Calvaruso¹, V. Di Marco¹

¹Section of Gastroenterology & Hepatology, Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy, ²Ph.D. program, Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Palermo, Italy, ³Endoscopy Service, Department of Diagnostic and Therapeutic Services, IRCCS - ISMETT Palermo, Italy, ⁴Section of Virology, Department of Health Promotion Sciences Maternal and Infant Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, Italy

Download

P 16
Significantly higher clinical and economic burden following diagnosis of Hepatitis D virus infection among U.S. adults with chronic Hepatitis B

R. Gish¹, R. Wong^2,3, C. Kim ⁴, G. Leung⁵, I. Jacobson⁶, J. Lim⁷, A. Kaushik ⁴

¹Hepatitis B Foundation, Doylestown PA USA, ²Stanford University School of Medicine, Stanford CA USA, ³VA Palo Alto Healthcare System, Palo Alto CA USA, ⁴HEOR - Global Value & Access, Gilead Sciences, CA, USA, ⁵RWE - Patient Safety, Gilead Sciences, CA, USA, ⁶NYU Grossman School of Medicine, New York NY USA, ⁷Yale University School of Medicine, New Haven CT USA

Download

P 17
Impact of HBV-HDV infection in a small town in central Italy

M. Maracci¹, B. Canovari¹, C. Temperoni¹, M. Balbucci¹, F. Barchiesi¹

¹UO Malattie Infettive-Ospedali Marche Nord-Pesaro, Italy

Download

P 18
Rising clinical and economic burden among chronic Hepatitis D patients who attended Spanish hospitals

M. Buti¹, A. Kaushik², M. Ascanio³, J. Darba⁴, N. Kachru²

¹Liver Unit. Hospital Universitario Valle Hebron, Barcelona, Spain, ²HEOR - Global Value & Access, Gilead Sciences, California, USA, ³BCN Health Economics & Outcomes Research SL, Barcelona, Spain, ⁴Department of Economics, University of Barcelona, Barcelona, Spain

Download

Hepatitis D antiviral treatment

P 19
Bulevirtide monotherapy in HDV patients with compensated cirrhosis and clinically significant portal hypertension

E. Degasperi¹, M.P. Anolli¹, S. Colonia Uceda Renteria², D. Sambarino¹, M. Borghi¹, R. Perbellini¹, C. Scholtes^3,4, F. Facchetti¹, A. Loglio¹, S. Monico¹, M. Fraquelli⁵, A. Costantino⁵, F. Ceriotti², F. Zoulim^3,4, P. Lampertico^1,6

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Virology Unit, Milan, Italy, ³Hepatology Department, Hospices Civils de Lyon (HCL) and Université Claude Bernard Lyon 1 (UCBL1), Lyon, France, ⁴INSERM U1052, Centre de Recherche sur le Cancer de Lyon (CRCL), ⁵Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Endoscopy, Milan, Italy, ⁶CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Download

P 20
Cure of Hepatitis Delta infection following 3 years of Bulevirtide monotherapy in a patient with compensated advanced cirrhosis

M.P. Anolli¹, E. Degasperi¹, L. Allweiss^2,3, S. Colonia Uceda Renteria ⁴, D. Sambarino¹, M. Borghi¹, R. Perbellini¹, A. Loglio¹, A. Sangiovanni¹, M. Maggioni⁵, C. Scholtes^6,7, F. Facchetti¹, F. Ceriotti², C. Neumann-Haefelin⁸, M. Dandri^2,3, F. Zoulim^6,7, P. Lampertico^1,9

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems site, Germany, ⁴Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Virology Unit, Milan, Italy, ⁵Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pathology Unit, Milan, Italy ⁶Hepatology Department, Hospices Civils de Lyon (HCL) and Université Claude Bernard Lyon 1 (UCBL1), Lyon, France, ⁷INSERM U1052, Centre de Recherche sur le Cancer de Lyon (CRCL), ⁸Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁹CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Download

P 21
Functional cure with lonafarnib-based therapy in chronic hepatitis delta

C. Yurdaydin^1,2,3, E. Yurdcu², M. Gümüşsoy¹, O. Keskin¹, G. Gençdal ³, M. Akyildiz ³, M. Zeybel ³, R. Idilman1,2 A. Mithat Bozdayi², I. Choong ⁴, S.G. Jeffrey⁵

¹Department of Gastroenterology, University of Ankara Medical School, ²Hepatology Institute, University of Ankara, Turkey, ³Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey

Download

P 22
Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience

C. Dietz-Fricke¹, F. Tacke², C. Zöllner², M. Demir², H. Schmidt ³, C. Schramm ³, K. Willuweit ³, C.M. Lange ⁴, S. Weber ⁴, G. Denk ⁴, C. Berg⁵, J. Grottenthaler⁵, Merle⁶, A. Olkus⁶, S. Zeuzem⁷, K. Sprinzl⁷, T. Berg⁸, F. van Bömmel⁸, J. Wiegand⁸, T. Herta⁸, T. Seufferlein⁹, E. Zizer⁹, N. Dipopoulos⁹, R. Thimme¹⁰, C. Neumann-Haefelin10, P. R. Galle¹¹, M. Sprinzl¹¹, A. Lohse¹², J. Schulze-zur-Wiesch¹², J. Kempski¹², A. Geier¹³, F.P. Reiter¹³, W.P. Hofmann¹⁴, P. Buggisch¹⁵, J. Goedicker¹⁶, B. Schlevogt¹⁶, J. Kahlhöfer¹, K. Port¹, B. Maasoumy¹, M. Cornberg¹, H. Wedemeyer¹, K. Deterding¹

¹Dept. of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Hannover, Germany, ²Dept. of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany, ³Dept. of Gastroenterology, Hepatology and Transplantational Medicine, University Hospital Essen, Essen, Germany, ⁴Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany, ⁵Department of Gastroenterology, Hepatology, and Infectiology, Medical Clinic, University of Tübingen, Tübingen, Germany, ⁶Department of Internal Medicine IV, University of Heidelberg, Heidelberg, Germany, ⁷Internal Medicine Department, Goethe University Hospital, Frankfurt, Germany, ⁸Division of Hepatology, Clinic and Polyclinic for Gastroenterology, Hepatology, Infectiology, and Pneumology, University Clinic Leipzig, Leipzig, Germany, ⁹Department of Internal Medicine I, University of Ulm, Ulm, Germany, ¹⁰Department of Medicine II, University Medical Centre Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ¹¹Department of Medicine I, University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany, ¹²Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ¹³University Hospital Würzburg, Dept. of medicine II, Würzburg, Germany, ¹⁴MVZ for Gastroenterology at Bayerischer Platz, Berlin, Germany, ¹⁵IFI - Institute for interdisciplinary medicine, Hamburg, Germany, ¹⁶Department of Medicine B, University Hospital Münster, Münster, Germany

Download

P 23
Once daily dosing of Lonafarnib and Ritonavir in patients with chronic Hepatitis Delta

O. Etzion¹, A. Nevo-Shor¹, C. Yurdaydin², D. Munteanu¹, Z. Lerner¹, E. Gane ³, I. Lipnitzky¹, A. Mushkalo¹, E. Brav¹, H. Abu-Kaf¹, S. Hameed⁴

¹Department of Gastroenterology and Liver Diseases, Soroka University Medical Center, Beersheva, Israel, ²Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey, ³Department of Gastroenterology and Hepatology, Auckland City Hospital, New Zealand, ⁴Aga Khan University and Hospital, Karachi, Pakistan

Download

P 24
Case report: liver cirrhosis HBV-HDV in a young woman on bulevirtide therapy

M. Maracci¹, P. Castelli², B. Canovari¹, C. Temperoni¹, L. Santilli¹, F. Barchiesi¹

¹Ospedali Riuniti Marche Nord, Pesaro, Italy, ²Anlaids, Macerata, Italy

Download

P 25
Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: combined intrahepatic results from the clinical trials MYR203 and MYR301

L. Allweiss^1,2, A. Volmari^1,2, Y. Ladiges¹, C. Eggers¹, V. Suri ³, J. Wallin ³, J. Flaherty ³, D. Manuilov ³, H. Wedemeyer^4,2, S. Urban^5,2, M. Lütgehetmann^1,2, J. Bockmann^1,2, M. Dandri^1,2

¹University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ²German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Hannover and Hei- delberg Partner Sites, ³Gilead Sciences, Inc, Foster City, CA, USA, ⁴Hannover Medical School, Hannover, Germany, ⁵University Hospital Heidelberg, Heidelberg, Germany

Download

P 26
Virological breakthrough after more than 48 weeks of complete HDV-RNA suppression on Bulevirtide therapy: a case report of 2 patients

C. Stern¹², J. Moussalli¹, M. Rudler¹, D. Thabut¹, V. Ratziu¹

¹Hôpital Pitié Salpêtrière, Paris, France, ²Hôpital Beaujon, Clichy, France

Download

P 27
Rescue of cirrhotic HBV/HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg

M. Bourlière¹, V. Loustaud-Ratti², C. Stern³, M. Bazinet⁴, S. Ben Ali¹, L. Lecomte¹, S. Francois², C. de Freitas³, A. Gerber⁵, S. Brichler⁵, E. Gordien⁵, A. Vaillant ⁴

¹Service Hépato-Gastro-Entérologie, Hôpital Saint-Joseph, Marseille, France, ²Service d’Hépato-Gastroentérologie, Centre hospitalier universitaire à Limoges, Limoges, France, ³Department de Hépatologie, AP-HP Hôpital Beaujon, Clichy, France, ⁴Replicor Inc. Montreal, Canada, ⁵Centre national de référence des hépatite B, C et Delta - Laboratoire associé, Hôpital Avicenne, Bobigny, France

Download

P 28
A biochemical basis for the hepatoprotective effects of REP 2139 during host mediated transaminase flares

A. Vaillant

Replicor Inc. Montreal, Canada

Download

P 29
Sustained off therapy control of HBV and HDV infection following removal of NAP-based therapy in cirrhotic HBV/HDV coinfection

A. Streinu-Cercel^1,2, A. Streinu-Cercel¹, M. Bazinet ³, C. Elsner ⁴, U. Dittmer ⁴, A.Vaillant³

¹National Institute of Infectious Diseases “Prof. Dr. Matei Bals” Bucharest, Romania, ²Carola Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Replicor Inc. Montreal, Canada, ⁴University Hospital Essen, Institute for Virology, Essen, Germany

Download

P 30
Antiviral treatment for Hepatitis delta virus (HDV): over 1000 unsolicited medical information requests from 39 countries over 18 months

S. Sandhu¹, L. Chen¹, G. Chee¹, C. Frenette¹, C. Hezode², B. Collins¹, A. Reiter¹, M. Mertens³

¹Gilead Sciences, Foster City, CA USA, ²Gilead Sciences, Paris, France, ³Gilead Sciences, Stockley Park, UK

Download

P 31
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel-design study

H. Wedemeyer¹, S. Aleman², M. Brunetto ³, A. Blank ⁴, P. Andreone⁵, P. Bogomolov⁶, V. Chulanov⁷, N. Mamonova⁷, N. Geyvandova⁸, V. Morozov⁹, O. Sagalova¹⁰, T. Stepanova¹¹, D. Manuilov¹², V. Suri¹², Q. An¹², J.F. Flaherty¹², A. Osinusi¹², J. Schulze zur Wiesch¹³, M. Cornberg¹, S. Zeuzem¹⁴, P. Lampertico^15,16

¹Clinic for Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany, ²Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institute, Stockholm, Sweden, ³Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa and Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany, ⁵Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁶State Budgetary Institution of Health Care of Moscow region “Moscow Regional Research Clinical Institute after M.F. Vladimirsky,” Moscow, Russia, ⁷FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁸Stavropol Regional Hospital, Stavropol, Russia, ⁹LLC Medical Company “Hepatolog”, Samara Russia, ¹⁰Federal State-Funded Institution of Higher Education “Southern Ural State Medical University of Ministry of Health of the Russian Federation,” Chelyabinsk, Russia, ¹¹LLC “Clinic of Modern Medicine,” Moscow, Russia, ¹²Gilead Sciences, Inc., Foster City, CA USA, ¹³Hepatology Outpatient Medical Clinic, University Hospital Hamburg-Eppendorf, Hamburg, Germany, ¹⁴Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany, ¹⁵Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ¹⁶CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Download

P 32
Integrated safety analysis of 24-week data from three Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

P. Lampertico^1,2, S. Aleman ³, T. Asselah ⁴, M. Bourliere⁵, A. Streinu-Cercel⁶, P. Bogomolov⁷, M. Viacheslav⁸, T. Stepanova⁹, S. Lazar¹⁰, V. Suri¹¹, D. Manuilov¹¹, L. Ye¹¹, J.F. Flaherty¹¹, A. Osinusi¹¹, M. Brunetto^12,13, H. Wedemeyer¹⁴

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²CRC “A. M. and A. Migliavacca” Center for Liver Disease, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, ³Karolinska University Hospital/Karolinska Institutet, Department of Infectious Diseases, Stockholm, Sweden, ⁴Hôpital Beaujon APHP, Université de Paris, INSERM, Clichy, France, ⁵Hôpital Saint Joseph Marseille, Marseille, France, ⁶Matei Bals National Institute of Infectious Diseases, Bucharest, Romania, ⁷State budgetary institution of health care of Moscow region “Moscow regional research clinical institute named after ¹¹M.F. Vladimirsky,” Moscow, Russia, ⁸LLC Medical Company “Hepatolog,” Samara, Russia, ⁹Limited liability company “Clinic of Modern Medicine,” Moscow, Russia, ¹⁰Dr. Victor Babes Foundation-Infectious and Tropical Diseases Hospital, Bucharest, Romania, ¹¹Gilead Sciences, Foster City, CA USA, ¹²University Hospital of Pisa, Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Pisa, Italy, ¹³University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy, ¹⁴Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany

Download

P 33
Integrated efficacy analysis of 24-week data from two Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose levels for treatment of chronic hepatitis delta

P. Lampertico^1,2, S. Aleman ³, A. Blank ⁴, P. Bogomolov⁵, V. Chulanov⁶, N. Mamonova⁶, M. Viacheslav⁷, O. Sagalova⁸, T. Stepanova⁹, V. Suri¹⁰, D. Manuilov¹⁰, L. Ye¹⁰, J.F. Flaherty¹⁰, A. Osinusi¹⁰, M. Cornberg¹¹, M. Brunetto^12,13, H. Wedemeyer¹²

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²CRC “A. M. and A. Migliavacca” Center for Liver Disease, University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, ³Karolinska University Hospital/Karolinska Institutet, Department of Infectious Diseases, Stockholm, Sweden, ⁴Heidelberg University Hospital, Clinical Pharmacology and Pharmacoepidemiology, Heidelberg, Germany, ⁵State budgetary institution of health care of Moscow region “Moscow regional research clinical institute named after M.F. Vladimirsky,” Moscow, Russia, ⁶FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁷LLC Medical Company “Hepatolog,” Samara, Russia, ⁸Federal state-funded institution of higher education “Southern Ural State Medical University of Ministry of Health of the Russian Federation,” Chelyabinsk, Russia, ⁹^5,6Limited liability company “Clinic of Modern Medicine,” Moscow, Russia, ¹⁰Gilead Sciences, Foster City, CA USA, ¹¹Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany, ¹²University Hospital of Pisa, Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Pisa, Italy, ¹³^5,6University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy

Download

P 34
No detectable resistance to bulevirtide in participants with chronic hepatitis D through 24 weeks of treatment

J. Hollnberger^1,2, Y. Liu ³, R. Martin ³, S. Manhas ³, T. Aeschbacher ³, S. Chang ³, S. Xu ³, B. Han ³, T. Yazdi ³, L. May ³, D. Han ³, K. Schöneweis ³, J.F. Flaherty ³, V. Suri ³,D. Manuilov ³, T. Asselah ⁴, P. Lampertico^5,6, H. Wedemeyer⁷, S. Aleman⁸, R. Mateo ³, E.S. Svarovskaia ³, H. Mo ³, S. Urban^1,2

¹University Hospital Heidelberg, Department of Molecular Virology, Heidelberg, Germany, ²German Center for Infection Research (DZIF), Heidelberg, Germany, ³Gilead Sciences, Inc., Foster City, CA USA, ⁴Hôpital Beaujon, Université de Paris, Clichy, France, ⁵Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy, ⁶”A.M. e A. Migliavacca” Center for the Study of Liver Disease, Università degli Studi di Milano, Milano, Italy, ⁷Medizinische Hochschule Hannover, Hannover, Germany, ⁸Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden

Download

P 35
Improvement of portal hypertension during viral suppression in patients with hepatitis delta - The ImPHrove-D study

L. Sandmann¹, T. L. Tergast¹, K. Deterding¹, H. Wedemeyer^1,2, B. Maasoumy^1,2

¹Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany, ²German Center for Infection Research (DZIF), Hannover/ Braunschweig, Germany

Download

P 36
Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort

F. Zoulim¹, C. Fougerou-Leurent², D. Roulot ³, S. Metivier ⁴, V. De Ledinghen⁵, V. Ratziu⁶, C. Stern⁶, P. Mathurin⁷, V. Loustaud-Ratti⁸, V. Leroy⁹, J. Dumortier¹⁰, C. Jezequel¹¹, D. Samuel¹², N. Ganne¹³, L. Alric¹⁴, A. Minello¹⁵, A. Abergel¹⁶, GP. Pageaux¹⁷, D. Alfaiate¹⁸, C. Lascoux-combe¹⁹, K. Lacombe²⁰, I. Rosa²¹, O. Chazouilleres²², G. Riachi²³, X. Causse²⁴, J. Chas²⁵, L. d’Alteroche²⁶, M. Bourliere²⁷, P. Carrieri²⁸, E. Gordien²⁹, J. Guedj³⁰, M. Levrero³¹, A. Renault², C. Scholtès³², L. Serfaty³³, C. Sureau³⁴, C. Birklé³⁵, E. Le Pabic², C. Tual², V. Petrov-Sanchez³⁵, H. Fontaine³⁶

¹Service d’Hépatologie et Gastroentérologie Hôpital de la Croix Rousse Lyon France, ²Service de Pharmacologie, CHU Pontchaillou INSERM, CIC 1414 Clinical Investigation Centre Rennes France, ³Unité Fonctionnelle d’Hépatologie, Hôpital Avicenne, Bobigny France, ⁴Service d’Hépato-gastroentérologie Hôpital Rangueil Toulouse France, ⁵Service d’Hépato-gastroentérologie Hôpital Haut-Lévêque Bordeaux France, ⁶Service d’Hépato- gastroentérologie APHP- Hôpital de La Pitié-Salpêtrière Paris France, ⁷Service des Maladies de l’Appareil Digestif Hôpital Claude Huriez, Lille, France, ⁸Service d’Hépato-gastroentérologie Hôpital Dupuytren Limoges France, ⁹Service d’Hépato-gastroentérologie Hôpital Henri Mondor Créteil France, ¹⁰Service d’Hépato-gastroentérologie HCL- Hôpital Edouard Herriot Lyon France, ¹¹Service des Maladies du Foie Hôpital Pontchaillou Rennes France, ¹²Centre Hépato-biliaire Hôpital Paul Brousse, Villejuif, France, ¹³Service d’Hépatologie Hôpital Avicenne Bobigny France, ¹⁴Service de Médecine Interne Hôpital Rangueil Toulouse France, ¹⁵Service d’Hépato-gastroentérologie Hôpital du Bocage Dijon France, ¹⁶Pôle Digestif et Hépatobiliaire Hôpital Estaing, Clermont-Ferrand, France, ¹⁷Service d’Hépato-gastroentérologie Hôpital Saint- Eloi, Montpellier, France, ¹⁸Service des Maladies Infectieuses et Tropicales Hôpital de la Croix Rousse, Lyon, France, ¹⁹Service des Maladies Infectieuses et Tropicales Hôpital Saint Louis, Paris, France, ²⁰Service des Maladies Infectieuses et Tropicales APHP- Hôpital Saint-Antoine Paris France, ²¹Médecine Interne et Hépato-gastroentérologie CHIC, Créteil, France, ²²Service d’Hépatologie Hôpital Saint Antoine, Paris, France, ²³Service d’Hépato-gastroentérologie Hôpital Charles Nicolle, Rouen, France, ²⁴Service d’Hépatogastroentérologie Hôpital de La Source, Orléans, France, ²⁵Service des Maladies Infectieuses et Tropicales APHP- Hôpital Tenon, Paris France, ²⁶Service d’Hépatogastroentérologie Hôpital Trousseau, Tours, France, ²⁷Service d’Hépato-gastroentérologie Hôpital Saint-Joseph Marseille France, ²⁸SESSTIM / U1252 Marseille France, ²⁹CNR des Hépatites B, C et Delta APHP- Hôpital Avicenne Bobigny France, ³⁰Infection. Antimicrobials. Modelling Evolution (IAME) - UMR 1137 Inserm Paris France, ³¹Cancer Research Center of Lyon (CRCL) - INSERM U1052 Lyon France, ³²Laboratoire de Virologie HCL- Hôpital de la Croix Rousse Lyon France, ³³Service d’hépatogastroentérologie HUS- Hôpital de Hautepierre Strasbourg France, ³⁴Laboratoire de Virologie Moléculaire Institut National de Transfusion Sanguine (INTS) Paris France, ³⁵ANRS | Maladies Infectieuses Emergentes Paris France, ³⁶Pôle d’Hépato-gastroentérologie, APHP-Hôpital Cochin, Paris, France

Download

P 37
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: an exploratory analysis of a Phase 3 trial at 48 weeks

M. Buti¹, H. Wedemeyer², S. Aleman ³, V. Chulanov ⁴, V. Morozov⁵, O. Sagalova⁶, T. Stepanova⁷, R. G. Gish⁸, A. Lloyd⁹, A. M. Kaushik¹⁰, V. Suri¹⁰, D. Manuilov¹⁰, A. O. Osinusi¹⁰, J. Flaherty¹⁰, P. Lampertico¹²

¹Hospital Universitario Valle Hebron, Barcelona, Spain, ²Medizinische Hochschule Hannover, Germany, ³Karolinska Universitetssjukhuset, Karolinska lnstitutet, Stockholm, Sweden, ⁴Central Research Institute of Epidemiology, Moscow, Russia, ⁵Hepatolog, LLC, Samara, Russian Federation, ⁶Southern Ural State Medical University, Chelyabinsk, Russian Federation, ⁷Clinic of Modern Medicine, Moscow, Russia, ⁸Robert G. Gish Consultants, LLC, San Diego, CA, USA, ⁹Acaster Lloyd Consulting Ltd, London, UK, ¹⁰Gilead Sciences, Inc., Foster City, CA, USA, ¹¹Foundation lRCCS Ca’ Granda Ospedale Maggiore Policlinico, CRC “A.M. and A. Migliavacca” Center for Liver Disease, University of Milan, Italy

Download

P 38
HBV RNA levels are associated with virological response to treatment with PEG-IFN in patients with chronic HDV infection

L. Sandmann¹, B. Bremer¹, C. Yurdaydin^2,3, K. Deterding¹, M. P. Manns^1,6, M. Cornberg^1,4,5,6, H. Wedemeyer^1,4,6, B. Maasoumy^1,5,6

¹Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany, ²Department of Gastroenterology, University of Ankara Medical School, Ankara, Turkey, ³Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey, ⁴German Center for Infection Research (DZIF), Partner Site HepNet Study-House, Hannover, Germany, ⁵Centre for Individualised Infection Medicine (CiiM), Helmholtz Centre for Infection Research, Germany, ⁶German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany

Download

P 39
Treatment with Bulevirtide (BLV) for 48 weeks reduces necroinflammation: results from a histological subset analysis of patients enrolled in studies MYR203 and MYR301

P. Lampertico¹, S. Aleman², T. Stepanova ³, M. Brunetto ⁴, Y. Guo⁵, V. Suri⁵, D. Manuilov⁵, C. Frenette⁵, J. Flaherty⁵, V. Chulanov⁶, M. Cornberg⁷, P. Bogolomov⁸, H. Wedemeyer⁷

¹Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, CRC “A.M. and A. Migliavacca” Center for Liver Disease, Università degli Studi di Milano, Milan, Italy, ²Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Clinic of Modern Medicine, Moscow, Russia, ⁴UO Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, ⁵Gilead Sciences, Inc. Foster City, CA USA, ⁶FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁷Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany, ⁸State budgetary institution of health care of Moscow region “Moscow regional research clinical institute named after M.F. Vladimirsky”, Moscow, Russia

Download

P 40
Elevations in total serum bile acids with bulevirtide treatment are asymptomatic and not associated with adverse events of interest in patients with chronic hepatitis D

P. Lampertico^1,2, S. Aleman ³, T. Asselah ⁴, A. Streinu-Cercel⁵, P. Bogomolov⁶, V. Morozov⁷, T. Stepanova⁸, S. Lazar⁹, D. Manuilov¹⁰, R.C. Mercier¹⁰, J.F. Flaherty¹⁰, C. Frenette¹⁰, V. Suri¹⁰, L. Ye¹⁰, S. Tseng¹⁰, F. Christian-Cox¹⁰, M. Brunetto¹¹, H. Wedemeyer¹²

¹Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, ²“A.M. e A. Migliavacca” Center for the Study of Liver Disease, Università degli Studi di Milano, Italy, ³Karolinska Universitetssjukhuset/Karolinska Institutet, Stockholm, Sweden, ⁴Hôpital Beaujon, Université de Paris, Clichy, France, ⁵Institutul Național de Boli Infecțioase “Prof. Dr. Matei Balț”, Bucureşti, Romania, ⁶Moscow Regional Research Clinical Institute Named After M. F. Vladimirsky, Moscow, Russian Federation, ⁷Hepatolog, Samara, Russian Federation, ⁸Clinic of Modern Medicine, Moscow, Russian Federation, ⁹Spitalului Clinic de Boli Infecţioase şi Tropicale, Dr.Victor Babeş, Bucureşti, ¹⁰Gilead Sciences, Inc., Foster City, California, USA, ¹¹Hepatology Unit, University Hospital of Pisa, Italy, ¹²Medizinische Hochschule Hannover, Germany

Download

P 41
Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline

K. Deterding¹, C.J. Xu^1,2, K. Port¹, B. Maasoumy¹, M. Cornberg^1,2, H. Wedemeyer¹

¹Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany, ²Center for Individualized Infection Medicine, CiiM, a joint venture between Hannover Medical School and the Helmholtz Center for Infection Research, Hannover, Germany

Download

Pathogenesis and Immunology

P 42
Outcomes of patients with active hepatitis delta infection after 15 years of follow up

V. Piazzolla¹, G. Cocomazzi¹, M.M. Squillante¹, N. Minerva², M.C. Cavorsi¹, A. Napolitano¹, F. Fraticelli¹, A. Mangia¹

¹Liver Unit, IRCCS “Casa Sollievo della Sofferenza San Giovanni Rotondo, Italy, ²Internal Medicine Ospedale Bonomo Andria, Italy

Download

P 43
Immunology of HDV in untreated and treated patients. A case report.

M. Radu¹, C. Timis¹, R. Baloi¹

¹National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, Bucharest, Romania

Download

P 44
Innate immune responses and liver damage pathways are highly activated in chronic hepatitis delta

E. García-Pras¹, T. Leonel¹, S. Rodríguez-Tajes¹, M. García-López¹, S. Lens¹, B. Testoni², Z. Mariño¹, A. Díaz ³, A. Rando ⁴, Y. Fundora⁵, F. Zoulim², X. Forns¹, S. Pérez-del-Pulgar¹

¹Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain, ²INSERM U1052-Cancer Research Center of Lyon (CRCL), University of Lyon, UMR_S1052, Lyon, France, ³Pathology Department, Biomedical Diagnostic Center, Hospital Clínic, CIBEREHD, Barcelona, Spain, ⁴Liver Pathology Unit, Department of Biochemistry and Microbiology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, CIBERehd, Barcelona, Spain, ⁵Hepatobilio-pancreatic and Liver Transplant Department, Hospital Clinic, Barcelona, Spain

Download

Virology

P 45
Quantification of serum HDV RNA by Robogene 2.0 in untreated and bulevirtide-treated HDV patients is significanlty influenced by the extraction methods

E. Degasperi¹, S. Colonia Uceda Renteria², M.P. Anolli¹, M. Borghi¹, D. Sambarino¹, R. Perbellini¹, F. Facchetti¹, S. Monico¹, F. Ceriotti², P. Lampertico ^1,3

¹Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy, ²Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Virology Unit, Milan, Italy, ³CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Download

P 46
Studying by next-generation sequencing the delta antigen quasispecies: complexity, variability and epitopes binding prediction

B. Pacin-Ruiz^1,2,3, M.F. Cortese^1,2,3, A. Palom ⁴, S. Garcia-Garcia^1,2,3, D. Tabernero^1,2,3, A. Rando-Segura⁵, A. Najarro¹, M. Vila^1,2,3, J. Gregori⁶, J. Quer⁶, M.Riveiro-Barciela^3,4, M. Buti^3,4, F. Rodriguez-Frias^1,2,3

¹Liver Pathology Unit, Departments of Biochemistry and Microbiology, Vall d’Hebron University Hospital, Barcelona, Spain, ²Clinical Biochemestry, Area of Immunomediated Diseases and Innovative Therapies, Vall d’Hebron Research Institute, Barcelona, Spain, ³Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain, ⁴Liver Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, Barcelona, Spain, ⁵Department of Microbiology, Vall d’Hebron University Hospital, Barcelona, Spain, ⁶Liver Unit, Liver Disease, Laboratory-Viral Hepatitis, Vall d’Hebron Institut Recerca, Barcelona, Spain

Download

The Poster Sessions have been realized with the support of

| Privacy & cookies | Terms of use |

Last update: 05.10.2022

Forgot password

Please enter your email address. You will receive a message with the link to reset your password.

Change password

Access to Reserved Area

Poster Exhibition

Diagnosis and Biomarkers

P 1 Virological diagnosis of Hepatitis Delta Virus infection in France: results of ten years of experience in organizing national quality controls

P 2 Divergent patterns of HBV-RNA AND HBcrAg levels in untreated chronic hepatitis Delta: a large European cross-sectional study

P 3 Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real world experience from Avicenne University Hospital, France

P 4 HBcrAg to quantitative anti-HBc IgG ratio predicts long-term outcomes in chronic hepatitis D patients

P 5 HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection

P 6 Clinical long-term outcome of hepatitis delta compared to HBV monoinfection

Epidemiology

P 7 Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study

P 8 Evaluating screening rates for hepatitis D in hepatitis B patients

P 9 Molecular clock analysis reveals an ancient origin but a recent radiation of hepatitis Delta virus in humans

P 10 Demographic features of HDV-infected patients from Republic of Moldova

P 11 High molecular diversity and remarkable geographical distribution of hepatitis Delta virus strains that are spreading in Cameroon

P 12 Evaluating Hepatitis Delta virus disease prevalence, incidence and patient characteristics among adults in Italy in the outpatient setting

P 13 Real-world analysis of healthcare resource utilization and costs among diagnosed Hepatitis D patients within the outpatient setting in Italy

P 14 Evaluation of HDV prevalence in outpatient clinic for infectious disease: from low to high endemic countries

P 15 The burden of HDV infection: a ten-years’ experience of a Sicilian tertiary centre of liver disease

P 16 Significantly higher clinical and economic burden following diagnosis of Hepatitis D virus infection among U.S. adults with chronic Hepatitis B

P 17 Impact of HBV-HDV infection in a small town in central Italy

P 18 Rising clinical and economic burden among chronic Hepatitis D patients who attended Spanish hospitals

Hepatitis D antiviral treatment

P 19 Bulevirtide monotherapy in HDV patients with compensated cirrhosis and clinically significant portal hypertension

P 20 Cure of Hepatitis Delta infection following 3 years of Bulevirtide monotherapy in a patient with compensated advanced cirrhosis

P 21 Functional cure with lonafarnib-based therapy in chronic hepatitis delta

P 22 Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience

P 23 Once daily dosing of Lonafarnib and Ritonavir in patients with chronic Hepatitis Delta

P 24 Case report: liver cirrhosis HBV-HDV in a young woman on bulevirtide therapy

P 25 Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: combined intrahepatic results from the clinical trials MYR203 and MYR301

P 26 Virological breakthrough after more than 48 weeks of complete HDV-RNA suppression on Bulevirtide therapy: a case report of 2 patients

P 27 Rescue of cirrhotic HBV/HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg

P 28 A biochemical basis for the hepatoprotective effects of REP 2139 during host mediated transaminase flares

P 29 Sustained off therapy control of HBV and HDV infection following removal of NAP-based therapy in cirrhotic HBV/HDV coinfection

P 30 Antiviral treatment for Hepatitis delta virus (HDV): over 1000 unsolicited medical information requests from 39 countries over 18 months

P 31 Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel-design study

P 32 Integrated safety analysis of 24-week data from three Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

P 33 Integrated efficacy analysis of 24-week data from two Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose levels for treatment of chronic hepatitis delta

P 34 No detectable resistance to bulevirtide in participants with chronic hepatitis D through 24 weeks of treatment

P 35 Improvement of portal hypertension during viral suppression in patients with hepatitis delta - The ImPHrove-D study

P 36 Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort

P 37 Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: an exploratory analysis of a Phase 3 trial at 48 weeks

P 38 HBV RNA levels are associated with virological response to treatment with PEG-IFN in patients with chronic HDV infection

P 39 Treatment with Bulevirtide (BLV) for 48 weeks reduces necroinflammation: results from a histological subset analysis of patients enrolled in studies MYR203 and MYR301

P 40 Elevations in total serum bile acids with bulevirtide treatment are asymptomatic and not associated with adverse events of interest in patients with chronic hepatitis D

P 41 Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline

Pathogenesis and Immunology

P 42 Outcomes of patients with active hepatitis delta infection after 15 years of follow up

P 43 Immunology of HDV in untreated and treated patients. A case report.

P 44 Innate immune responses and liver damage pathways are highly activated in chronic hepatitis delta

Virology

P 45 Quantification of serum HDV RNA by Robogene 2.0 in untreated and bulevirtide-treated HDV patients is significanlty influenced by the extraction methods

P 46 Studying by next-generation sequencing the delta antigen quasispecies: complexity, variability and epitopes binding prediction

P 1
Virological diagnosis of Hepatitis Delta Virus infection in France: results of ten years of experience in organizing national quality controls

P 2
Divergent patterns of HBV-RNA AND HBcrAg levels in untreated chronic hepatitis Delta: a large European cross-sectional study

P 3
Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real world experience from Avicenne University Hospital, France

P 4
HBcrAg to quantitative anti-HBc IgG ratio predicts long-term outcomes in chronic hepatitis D patients

P 5
HBcrAg tightly correlates with elevated HDV replicative activity and with enhanced liver inflammation and damage: role of HBcrAg as a biomarker of liver disease progression in the setting of HDV co-infection

P 6
Clinical long-term outcome of hepatitis delta compared to HBV monoinfection

P 7
Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study

P 8
Evaluating screening rates for hepatitis D in hepatitis B patients

P 9
Molecular clock analysis reveals an ancient origin but a recent radiation of hepatitis Delta virus in humans

P 10
Demographic features of HDV-infected patients from Republic of Moldova

P 11
High molecular diversity and remarkable geographical distribution of hepatitis Delta virus strains that are spreading in Cameroon

P 12
Evaluating Hepatitis Delta virus disease prevalence, incidence and patient characteristics among adults in Italy in the outpatient setting

P 13
Real-world analysis of healthcare resource utilization and costs among diagnosed Hepatitis D patients within the outpatient setting in Italy

P 14
Evaluation of HDV prevalence in outpatient clinic for infectious disease: from low to high endemic countries

P 15
The burden of HDV infection: a ten-years’ experience of a Sicilian tertiary centre of liver disease

P 16
Significantly higher clinical and economic burden following diagnosis of Hepatitis D virus infection among U.S. adults with chronic Hepatitis B

P 17
Impact of HBV-HDV infection in a small town in central Italy

P 18
Rising clinical and economic burden among chronic Hepatitis D patients who attended Spanish hospitals

P 19
Bulevirtide monotherapy in HDV patients with compensated cirrhosis and clinically significant portal hypertension

P 20
Cure of Hepatitis Delta infection following 3 years of Bulevirtide monotherapy in a patient with compensated advanced cirrhosis

P 21
Functional cure with lonafarnib-based therapy in chronic hepatitis delta

P 22
Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience

P 23
Once daily dosing of Lonafarnib and Ritonavir in patients with chronic Hepatitis Delta

P 24
Case report: liver cirrhosis HBV-HDV in a young woman on bulevirtide therapy

P 25
Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: combined intrahepatic results from the clinical trials MYR203 and MYR301

P 26
Virological breakthrough after more than 48 weeks of complete HDV-RNA suppression on Bulevirtide therapy: a case report of 2 patients

P 27
Rescue of cirrhotic HBV/HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg

P 28
A biochemical basis for the hepatoprotective effects of REP 2139 during host mediated transaminase flares

P 29
Sustained off therapy control of HBV and HDV infection following removal of NAP-based therapy in cirrhotic HBV/HDV coinfection

P 30
Antiviral treatment for Hepatitis delta virus (HDV): over 1000 unsolicited medical information requests from 39 countries over 18 months

P 31
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel-design study

P 32
Integrated safety analysis of 24-week data from three Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

P 33
Integrated efficacy analysis of 24-week data from two Phase 2 and one Phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose levels for treatment of chronic hepatitis delta

P 34
No detectable resistance to bulevirtide in participants with chronic hepatitis D through 24 weeks of treatment

P 35
Improvement of portal hypertension during viral suppression in patients with hepatitis delta - The ImPHrove-D study

P 36
Real life study of bulevirtide in chronic hepatitis Delta: preliminary results of the ANRS I MIE HD EP01 HDV prospective cohort

P 37
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: an exploratory analysis of a Phase 3 trial at 48 weeks

P 38
HBV RNA levels are associated with virological response to treatment with PEG-IFN in patients with chronic HDV infection

P 39
Treatment with Bulevirtide (BLV) for 48 weeks reduces necroinflammation: results from a histological subset analysis of patients enrolled in studies MYR203 and MYR301

P 40
Elevations in total serum bile acids with bulevirtide treatment are asymptomatic and not associated with adverse events of interest in patients with chronic hepatitis D

P 41
Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline

P 42
Outcomes of patients with active hepatitis delta infection after 15 years of follow up

P 43
Immunology of HDV in untreated and treated patients. A case report.

P 44
Innate immune responses and liver damage pathways are highly activated in chronic hepatitis delta

P 45
Quantification of serum HDV RNA by Robogene 2.0 in untreated and bulevirtide-treated HDV patients is significanlty influenced by the extraction methods

P 46
Studying by next-generation sequencing the delta antigen quasispecies: complexity, variability and epitopes binding prediction